Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

Abstract Background It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the ef...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Yuri Komaki, Yoshinori Ozono, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Mitsue Sueta, Tadashi Miike, Shojiro Yamamoto, Hirofumi Uto, Kazunori Kusumoto, Toshimasa Ochiai, Junya Kato, Naoto Komada, Kazuo Kuroki, Toshiharu Eto, Masafumi Shigehira, Shuichi Hirono, Kenji Nagata, Hiroshi Kawakami
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMC 2022-04-01
श्रृंखला:BMC Gastroenterology
विषय:
Chronic hepatitis C
Direct-acting antivirals
Glecaprevir
Pibrentasvir
Sustained virological response
ऑनलाइन पहुंच:https://doi.org/10.1186/s12876-022-02284-z
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन